Clinical trials: Anlotinib
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
According to the definition of National Comprehensive Cancer Network (NCCN), ovarian clear cell carcinoma (OCCC) is a less common subtype of epithelial ovarian cancer (EOC) .
- Trial name
- CC-ANNIE (NCT05130515)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ewing's Tumor Metastatic
Anlotinib and Irinotecan for Ewing Sarcoma
The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
- Trial name
- NCT03416517
- Testing
- Anlotinib, Irinotecan
- Where
- 5 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University People's Hospital
Pancreatic Neoplasms
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
- Trial name
- NCT06767813
- Testing
- TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Soft Tissue Sarcoma (STS)
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
This study intends to enroll patients with advanced soft tissue sarcoma, employing immunotherapy combined with eribulin, anlotinib, and radiotherapy as subsequent-line treatment to preliminarily explore its efficacy and safety.
- Trial name
- NCT07205185
- Testing
- QL1706 + Eribulin + Anlotinib + Radiotherapy
- Volunteers
- 46 people
- Sponsor
- Fudan University
Non-Small-Cell Lung
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high.
- Trial name
- NCT03766490
- Testing
- Anlotinib Hydrochloride, Gefitinib, Icotinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- The First Affiliated Hospital of Soochow University
SCLC, Extensive Stage
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of…
- Trial name
- NCT04660097
- Testing
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with…
- Trial name
- NCT05271916
- Testing
- Dacomitinib+Anlotinib, Dacomitinib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Chest Hospital
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy.
- Conditions
- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib, Peg-aspargase
- Trial name
- NCT03936452
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Ovarian Neoplasms, Fallopian Tube Neoplasms
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
- Trial name
- NCT04807166
- Testing
- Drug: Anlotinib, Drug: Carboplatin/Paclitaxel
- Where
- 6 sites in China
- Volunteers
- 56 people
- Sponsor
- Wenjun Cheng
Non-small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2.
- Trial name
- NCT02029209
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Metastatic Pancreatic Cancer
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after…
- Trial name
- NCT06662006
- Testing
- nal-IRI,5-fu,LV, benmelstobart, anlotinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Carcinoma
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
This study is divided into three phases: single-dose exploration, combination dosage exploration and cohort expansion. The Single-dose exploration stage aims to evaluate the tolerability of TQB2858 injection in subjects with…
- Trial name
- NCT05193604
- Testing
- TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Lung Neoplasms
Anlotinib Therapy in Patients With Advanced Lung Cancer.
Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer.
- Trial name
- NCT03940404
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First People's Hospital of Hangzhou
Advanced Squamous Non-Small Cell Lung Carcinoma
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450…
- Trial name
- NCT05718167
- Testing
- TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
- Where
- 4 sites in China
- Volunteers
- 570 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Medullary Thyroid Cancer (MTC)
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
This trial is a prospective, observational Phase II clinical study. For patients with locally advanced and/or metastatic medullary thyroid carcinoma with RET gene mutations who require systemic treatment, they are randomly…
- Trial name
- NCT07048964
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colo-rectal Cancer
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer
Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of this prospective non-randomised study in an escalated dose cohort.
- Trial name
- NCT03545711
- Testing
- Anlotinib Hydrochloride with Irinotecan
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Cancer
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
This study was a single-arm, open-label, phase II study of PD-1 monoclonal antibody combined with anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR uncommon mutations.
- Trial name
- NCT04790409
- Testing
- sintilimab and anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Non-small Cell Lung Cancer
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
To evaluate the efficacy and safety of almonertinib plus anlotinib as first-line treatment for advanced non-small cell lung cancer with EGFR sensitive mutation and TP53 mutation. This study is an exploratory single-arm study.
- Trial name
- NCT06043973
- Testing
- almonertinib
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Qianfoshan Hospital
To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
To observe the efficacy and safety of hydrochloride anlotinib combined with concurrent radiochemotherapy for patients with FIGO stage IB3 and IIA2-IVA cervical cancer.
- Trial name
- NCT05772377
- Testing
- Hydrochloride anlotinib, cis Platinum/carboplatin, External beam radiotherapy and brachytherapy
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
In recent years, with the emergence and clinical application of anti-angiogenesis therapy, the therapeutic effect of patients has been significantly improved while ensuring that the adverse reactions of patients do not increase.
- Trial name
- NCT06341530
- Testing
- anlotinib combined with penpulimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University